Previous 10 | Next 10 |
-- -Requested Meeting with FDA to Discuss Next Steps in Development of CAP-1002 for Duchenne Muscular Dystrophy- -Data for Phase II INSPIRE Clinical Trial Expected in Third Quarter- -Plan to File IND for Multivalent Exosome-mRNA Vaccine for SARS-CoV-2 in Third Quarter- -To Hos...
--Conference Session: Therapeutic Applications of Extracellular Vesicles: From Diagnostics to Drug Delivery-- LOS ANGELES, May 12, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell- and exos...
LOS ANGELES, May 06, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial resu...
Capricor Therapeutics shares climb ([[CAPR]] +6.3%) after signing an exclusive, worldwide licensing agreement with Johns Hopkins University ((JHU)) to include engineered exosomes for vaccines and therapeutics as part of the company’s exosome technology portfolio.Under the ter...
Gainers: Galera Therapeutics (GRTX) +26%, Ocular Therapeutix (OCUL) +17%, Capricor Therapeutics (CAPR) +15%, AtriCure (ATRC) +12%, Atossa Therapeutics (ATOS) +14%.Losers: Adverum Biotechnologies (ADVM) -60%, Cara Therapeutics (CARA) -44%,...
Galera Therapeutics (GRTX) +41% on updating data from pancreatic cancer trial.Willamette Valley Vineyards (WVVI) +18%.Nokia Corporation (NOK) +17% on Q1 results.VEREIT (VER) +17% as Realty Income to acquire the company.Enlivex Therapeutics (ENLV) +13%.Pluristem Therapeutics (PS...
LOS ANGELES, April 29, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, today announced that it has s...
The institutions and companies involved in genetics now lend support to most other areas of life sciences. The contributions include the discovery of genetic markers of disease and gene therapy. The market for genetic testing continues to grow in leaps and bounds, and has gained momentum as th...
Capricor Therapeutics, Inc. (CAPR) Q4 2020 Earnings Conference Call March 11, 2021 4:30 PM ET Company Participants AJ Bergmann – Chief Financial Officer Linda Marbán – Chief Executive Officer Stephen Gould – Executive Consultant Conference Call Participants Michael O...
Capricor Therapeutics (CAPR): Q4 GAAP EPS of -$0.21 misses by $0.01.Revenue of $0.05M (-77.3% Y/Y)Shares -0.7% AH.Press Release For further details see: Capricor Therapeutics EPS misses by $0.01
News, Short Squeeze, Breakout and More Instantly...
Capricor Therapeutics Inc. Company Name:
CAPR Stock Symbol:
NASDAQ Market:
Capricor Therapeutics Inc. Website:
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is set to join the Russell 2000 ® Index an...
-Results in Performance of the Upper Limb (PUL v2.0) Continue to Show Slowing of Disease Progression in Later-Stage DMD Patients- -Improvements Seen in Multiple Cardiac Endpoints Demonstrating Stabilization of Cardiac Function Over 3 Years of Treatment- -Pre-BLA Meeting with FDA...
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- In a release issued under the headline "Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy" on Tuesday, June 25th by Capricor Therapeutics, please note that the words "Pre-BLA Meeting with FDA for Deramiocel" were omitted ...